OBJECTIVE: Adipokines have been implicated in the pathogenesis of metabolic syndrome (MetS) and insulin resistance. We investigated the association between these conditions and serum levels of visfatin, adiponectin and leptin. MATERIAL AND METHODS: 175 overweight and obese boys and girls aged 3-17 years. MetS was defined as presence of at least three of the following: triglycerides >or= 1.24 mmol/L, high-density lipoprotein cholesterol <or= 1.03 mmol/L, fasting glucose >or= 6.1 mmol/L, elevated waist circumference and systolic or diastolic blood pressure >or= 90th percentile. RESULTS: After adjustment for age and gender visfatin levels were significantly higher (median 19.0 [25th, 75th percentiles 11.9 , 37.1] vs. 15.2 [11.6 , 21.1] ng/ml; p(adjusted) = 0.02) in subjects with MetS (n = 41) compared to subjects without (n = 134). There were no significant differences in adiponectin or leptin levels between the two groups after adjustment for age and gender. Visfatin levels increased proportionally with number of MetS components (beta = 0.16, 95%CI 0.04, 0.28; p(adjusted) = 0.01), and adiponectin levels decreased proportionally with number of components (beta = -0.11, 95%CI -0.18, -0.04; p(adjusted) = 0.002). Leptin levels were not related to number of components of MetS. Unlike visfatin, both adiponectin (beta = -0.24, 95%CI -0.33, -0.15; p adjusted < 0.001) and leptin (beta = 0.14, 95%CI 0.01, 0.28; p adjusted = 0.03) were associated with insulin resistance. CONCLUSION: The elevation of visfatin observed in children and adolescents with MetS was proportionate to number of components of MetS but was not associated with insulin resistance. The increase in visfatin may contribute to low-grade systemic inflammation associated with MetS.
OBJECTIVE: Adipokines have been implicated in the pathogenesis of metabolic syndrome (MetS) and insulin resistance. We investigated the association between these conditions and serum levels of visfatin, adiponectin and leptin. MATERIAL AND METHODS: 175 overweight and obeseboys and girls aged 3-17 years. MetS was defined as presence of at least three of the following: triglycerides >or= 1.24 mmol/L, high-density lipoprotein cholesterol <or= 1.03 mmol/L, fasting glucose >or= 6.1 mmol/L, elevated waist circumference and systolic or diastolic blood pressure >or= 90th percentile. RESULTS: After adjustment for age and gender visfatin levels were significantly higher (median 19.0 [25th, 75th percentiles 11.9 , 37.1] vs. 15.2 [11.6 , 21.1] ng/ml; p(adjusted) = 0.02) in subjects with MetS (n = 41) compared to subjects without (n = 134). There were no significant differences in adiponectin or leptin levels between the two groups after adjustment for age and gender. Visfatin levels increased proportionally with number of MetS components (beta = 0.16, 95%CI 0.04, 0.28; p(adjusted) = 0.01), and adiponectin levels decreased proportionally with number of components (beta = -0.11, 95%CI -0.18, -0.04; p(adjusted) = 0.002). Leptin levels were not related to number of components of MetS. Unlike visfatin, both adiponectin (beta = -0.24, 95%CI -0.33, -0.15; p adjusted < 0.001) and leptin (beta = 0.14, 95%CI 0.01, 0.28; p adjusted = 0.03) were associated with insulin resistance. CONCLUSION: The elevation of visfatin observed in children and adolescents with MetS was proportionate to number of components of MetS but was not associated with insulin resistance. The increase in visfatin may contribute to low-grade systemic inflammation associated with MetS.
Authors: V A Belo; M R Luizon; R Lacchini; J A Miranda; C M M Lanna; D C Souza-Costa; J E Tanus-Santos Journal: Int J Obes (Lond) Date: 2013-09-12 Impact factor: 5.095
Authors: Hassan M Salama; Ashraf Galal; Ayat A Motawie; Ashraf F Kamel; Doaa M Ibrahim; Azza A Aly; Emman A Hassan Journal: Open Access Maced J Med Sci Date: 2015-11-26
Authors: Mohammad Sadegh Fazeli; Mohammad Reza Keramati; Azam Rahimi; Alireza Kazemeini; Mohammad Mehdi Banoei; Habibollah Dashti; Amir Reza Fazeli Journal: Med J Islam Repub Iran Date: 2016-01-24
Authors: Eloi Franco-Trepat; María Guillán-Fresco; Ana Alonso-Pérez; Alberto Jorge-Mora; Vera Francisco; Oreste Gualillo; Rodolfo Gómez Journal: J Clin Med Date: 2019-08-07 Impact factor: 4.241